Disease · MONDO_0005312
pouchitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pouchitis. Diseases, record MONDO_0005312. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005312
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ALICAFORSEN | CHEMBL2108326 | Oligonucleotide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| USTEKINUMAB | CHEMBL1201835 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VEDOLIZUMAB | CHEMBL1743087 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAURURSODIOL | CHEMBL272427 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| URSODIOL | CHEMBL1551 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CHARCOAL, ACTIVATED | CHEMBL2106049 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TOFACITINIB | CHEMBL221959 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VIMEKOFUSP | CHEMBL5314977 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLOTRIMAZOLE | CHEMBL104 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FOSFOMYCIN | CHEMBL1757 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CSF2RA | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1438 | Drugs and targets |
| CSF2RB | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1439 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 1 | Granulocyte colony stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| ICAM1 | Intercellular adhesion molecule-1 mRNA 3'UTR | 1 | Intercellular adhesion molecule-1 mRNA 3'UTR antisense inhibitor | Phase 3 | https://conductscience.org/library/genes/3383 | Drugs and targets |
| IL12A | Interleukin-12 | 1 | Interleukin-12 inhibitor | Phase 3 | https://conductscience.org/library/genes/3592 | Drugs and targets |
| IL12B | Interleukin-12 | 1 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Phase 3 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 1 | Interleukin-23 inhibitor | Phase 3 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| ITGA4 | Integrin alpha-4/beta-7 | 1 | Integrin alpha-4/beta-7 inhibitor | Phase 3 | https://conductscience.org/library/genes/3676 | Drugs and targets |
| ITGB7 | Integrin alpha-4/beta-7 | 1 | Integrin alpha-4/beta-7 inhibitor | Phase 3 | https://conductscience.org/library/genes/3695 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02525523 | Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics | Phase 3 | 138 | 2020-02-25 | Pouchitis | ALICAFORSEN | Its record names the disease | ClinicalTrials.gov |
| NCT04580277 | Tofacitinib For Treatment Of Chronic Pouchitis | Phase 2 | 6 | 2024-04-04 | Pouchitis, Ileal Pouchitis, Ileal Pouch | TOFACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT06443502 | A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis | Phase 3 | 30 | Pouchitis | VEDOLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04741087 | Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis | Phase 2 | 22 | Pouchitis | VIMEKOFUSP | Its record names the disease | ClinicalTrials.gov | |
| NCT04089345 | Stelara fOr ChRonic AntibioTic rEfractory pouchitiS | Phase 3 | 20 | Pouchitis | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00583076 | Safety and Efficacy of AST-120 in the Treatment of Pouchitis | Phase 2 | 19 | Pouchitis | CHARCOAL, ACTIVATED | Its record names the disease | ClinicalTrials.gov | |
| NCT04979832 | GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery | Phase 1/2 | 18 | Pouchitis | FOSFOMYCIN, METRONIDAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00061282 | Clotrimazole Enemas for Pouchitis in Children and Adults | Phase 1/2 | 11 | Ulcerative Colitis, Pouchitis, Ileitis, Inflammatory Bowel Disease | CLOTRIMAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT07469189 | A Study on Hydroxocobalamin Given to Healthy Individual to Monitor Symptoms | Phase 1 | 10 | Hydroxocobalamin Adverse Reaction | HYDROXOCOBALAMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00583531 | Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis | Phase 2 | 2 | Pouchitis | CHARCOAL, ACTIVATED | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alicaforsen vs Placebo: deaths from any cause | 0 of 69 | 0 of 69 | 138 | NCT02525523 | Trial comparisons |
| Alicaforsen vs Placebo: serious adverse events | 4 of 69 | 2 of 69 | 138 | NCT02525523 | Trial comparisons |
| Alicaforsen vs Placebo: Proportion of Patients With Endoscopic Remission | 3 of 65 | 3 of 61 | 126 | NCT02525523 | Trial comparisons |
| Alicaforsen vs Placebo: Proportion of Patients With a Reduction in Relative Stool Frequency | 22 of 65 | 16 of 61 | 126 | NCT02525523 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005312
GET https://conductscience.org/api/diseases/v1/MONDO_0005312/drugs